# Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b

> **NCT06967987** · PHASE2 · WITHDRAWN · sponsor: **Institut Cancerologie de l'Ouest**

## Conditions studied

- Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas
- Overexpression FGFR2b

## Interventions

- **DRUG:** Bemarituzumab + Flot regimen

## Key facts

- **NCT ID:** NCT06967987
- **Lead sponsor:** Institut Cancerologie de l'Ouest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-01-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Discontinuation of product manufacturing by the funder prior to the start of participant enrollment
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06967987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06967987, "Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06967987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*